Kite Pharma is a cell therapy company founded in 2009 as a pioneer in cell therapy research. It researches, develops, manufactures, and commercializes cell therapies, including CAR T-cell therapies, and opened its commercial manufacturing site in El Segundo in 2016. Acquired by Gilead Sciences in 2017, Kite operates as an independent operating company within Gilead.
Volta TherapeuticsVolta Therapeutics creates an automated, closed system cell therapy manufacturing technology that brings GMP suites directly to the clinic. The company provides capacity, automation, and customization through continuous manufacturing devices to facilitate streamlined GMP cell therapy manufacturing.MARS, PA
Tinkeso Therapeutics, IncFrom its base in Valhalla, Tinkeso Therapeutics develops off-the-shelf, allogeneic Natural Killer T (NKT) cell therapies for cancers and autoimmune disorders. Formerly known as Akeso Therapeutics, the early-stage biotech combines native and engineered NKT programs, including a non-genome-edited CD7 CAR-iNKT therapy aimed at blood cancers and a native type III NKT approach for acute myeloid leukemia. Its proprietary expansion platform is designed to produce at least 100 doses of CAR-modified iNKT cells from a single donor leukopak.VALHALLA, NY
CEL-SCI CorporationFormed in 1983, CEL-SCI Corporation is a biotechnology company conducting drug discovery, research, development, and manufacturing of complex biological substances. Its pipeline centers on investigational immune-based therapies, including Multikine, developed for potential use in cancer, and LEAPS candidates for autoimmune and infectious diseases. The company operates a dedicated manufacturing facility for investigational Multikine.ELKRIDGE, MD
Innovative Cellular TherapeuticsHeadquartered in Rockville, Innovative Cellular Therapeutics is a private clinical-stage biotechnology company developing cellular immunotherapies for solid tumors. Its proprietary CoupledCAR® platform underpins individually made CAR-T therapies, including the lead GCC19CART program being studied for relapsed or refractory metastatic colorectal cancer. Founded by Larry Lei Xiao and Zoe Zhao Wu, ICT combines more than 20 years of stem-cell, cell-therapy and gene-editing experience with FDA cellular-therapy review expertise.ROCKVILLE, MD